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Abstract
Background: Magnetic resonance imaging (MRI) enables a more sensitive detection of brain metastasis and
stereotactic irradiation (SRI) efficiently controls brain metastasis. In limited-stage small cell lung cancer (LS-SCLC),
prophylactic cranial irradiation (PCI) in patients with good responses to initial treatment is recommended based on
the survival benefit shown in previous clinical trials. However, none of these trials evaluated PCI effects using the
management of brain metastasis with MRI or SRI. This study aimed to determine the effects of MRI and SRI on the
benefits of PCI in patients with LS-SCLC.
Methods: The clinical records of pathologically proven SCLC from January 2006 to June 2013 in facilities equipped
with or had access to SRI in Japan were retrospectively reviewed. Patients with LS-SCLC and complete or good
partial responses after initial treatment were included in the study and analyzed by the Kaplan-Meier method.
Results: Of 418 patients with SCLC, 124 met criteria and were divided into patients receiving PCI (PCI group; n = 29)
and those without PCI (non-PCI groups; n = 95). At baseline, ratios of patients with stage III were significantly
advantageous for the non-PCI group, although younger age and high ratios of complete response and MRI
confirmed absence of brain metastasis were advantageous for the PCI group. Neither median survival times
(25 vs. 34 months; p = 0.256) nor cumulative incidence of brain metastasis during 2 years (45.5 vs. 30.8 %; p = 0.313)
significantly differed between the two groups. Moreover, these factors did not significantly differ among patients
with stage III disease (25 vs. 26 months; p = 0.680, 42.3 vs. 52.3 %; p = 0.458, respectively).
Conclusion: PCI may be less beneficial in patients with LS-SCLC if the management with MRI and SRI is available.
Keywords: Small cell lung cancer, Prophylactic cranial irradiation, Stereotactic irradiation, Magnetic resonance
imaging, Brain metastasis
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Background
Small cell lung cancer (SCLC) comprises approxi-
mately 15 % of all lung cancers, and usually pro-
gresses rapidly and preferentially metastasizes to the
brain. Even with early detection before distant metas-
tasis and curative treatments, 50–60 % of patients
with SCLC develop brain metastasis (BM) within
2 years [1–4]. Because the presence of BM indicates
poor prognosis, patients with SCLC and symptomatic
or asymptomatic BM have median survival times
(MSTs) of only 4–8 months even under systemic
treatment [5].
Several clinical trials have evaluated the efficacy of
prophylactic cranial irradiation (PCI), and most have
shown significant reductions in the occurrence of BM
and survival improvement in patients with limited-
stage SCLC (LS-SCLC) and good responses to initial
treatment [1–4]. However, to our knowledge, only two
of the 17 reported trials required confirmation of the
absence of BM before PCI with contrast-enhanced
computed tomography (CT) [6, 7], and none of them
used magnetic resonance imaging (MRI) for detecting
BM [1–4, 6–20].
Seute et al. revealed that BM was detected in 10 % of
patients with SCLC during the CT era and in 24 % dur-
ing the MRI era, and the adaptation of MRI decreased
the frequency of PCI from 42 to 13 % [21]. Moreover,
Manapov et al. reported that cranial MRI immediately
before PCI detected BM in 32.5 % of patients with LS-
SCLC who had been assessed with complete response
(CR) [22]. Thus, a strict selection of patients receiving
PCI, which excludes those who have BM after the initial
treatment using cranial MRI, may affect BM occur-
rence, survival times, and PCI benefits. However, no
studies evaluated PCI effects in such a cohort.
SRI is recently reported to be capable of controlling
single or multiple BM, at least locally, among patients
with cancer, including SCLC [23–25], and it is exten-
sively used in clinical practice in Japan, although the
improvement of survival time by SRI remains unknown.
Harris et al. reported that SRI efficiently controlled BM
in patients with a poor prognosis of SCLC who devel-
oped BM after PCI or whole brain radiotherapy
(WBRT) [24] The MST of 5.9 months indicated that
administering SRI to patients with BM could prolong
survival time. Although more evidence is required, SRI
could also affect the importance of PCI.
We hypothesized that precise patient selection with-
out BM using cranial MRI immediately before PCI and
efficient local control of BM with SRI may limit previ-
ously reported benefits of PCI. In the present study, we
retrospectively compared the incidences of BM and sur-
vival time between PCI-treated and -untreated patients
in facilities with access to MRI and SRI.
Methods
Data from patients with pathologically proven SCLC
were collected from January 2006 to June 2013 at the
Hamamatsu University School of Medicine, Seirei
Mikatahara General Hospital, Shizuoka General Hos-
pital, and Iwata City Hospital. All four participating fa-
cilities were cancer-designated hospitals in Japan and
were equipped with or had access to SRI and MRI.
Medical records were reviewed, and age, sex, smoking
history, laboratory findings, type of and response to
initial treatment, treatment for BM, and outcomes
were analyzed. The study was approved by the Institu-
tional Review Board of Hamamatsu University School
of Medicine, Seirei Mikatahara General Hospital, Iwata
City Hospital, and Shizuoka General Hospital.
Of 418 newly diagnosed patients with SCLC during this
period, 124 patients with LS-SCLC with CR or good partial
response (gPR) to initial treatment were enrolled in this
study. Disease stages were determined based on the initial
staging investigations, including chest and abdomen CT,
bone screening by whole-body 18F-fluorodeoxyglucose
positron emission tomography or scintigraphy, and brain
screening using contrast-enhanced CT or MRI. Limited-
stage was defined as limited disease originating from the
hemithorax that may include the mediastinum or supracla-
vicular lymph nodes. Malignant pleural or pericardial effu-
sions and contralateral supraclavicular lymph nodes were
excluded.
Patients who developed BM during treatment were
preferentially treated with SRI following discussions
with radiation oncologists. The response to initial treat-
ment was determined by imaging tests requested by the
treating doctors and were interpreted by the reporting
radiologist. According to RECIST version 1.1, CR was
characterized by the disappearance of all target and
non-target lesions and the reduction of short axes of all
lymph nodes to <10 mm with tumor marker levels at
less than the reference range. Similarly, gPR was de-
fined as the disappearance of lesions, but with elevated
or unknown tumor marker levels and 10–15-mm short
axes of lymph nodes. Chest CT was used to distinguish
between CR and gPR. Although cranial scans after ini-
tial treatment were unnecessary, contrast-enhanced
MRI was preferentially used for confirming the absence
of BM.
Overall survival was defined as the interval between
the date of pathological diagnosis and that of the final
follow-up visit or death, and survival time after BM de-
tection was defined as the interval between the date of
BM detection with any imaging modality and that of the
final follow-up visit or death. MST and the cumulative
incidence of BM were estimated by the Kaplan-Meier
method [26], and groups were compared using the log-
rank test. Categorical data were compared between
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groups using the chi-square test for independence, and
continuous data were compared using Student’s t- test
[27]. All tests were two-sided, and a p-value of <0.05
was considered statistically significant. All statistical ana-
lyses were performed using the PASW Statistics version
18.0 for Windows (SPSS Inc., Chicago, USA).
Results
After enrollment, 124 patients were divided into PCI-
treated (PCI group; n = 29) and untreated (non-PCI
group; n = 95) patients. At baseline, the ratio of clinical
stage III patients was significantly higher in the PCI
group than the non-PCI (82.8 vs. 51.6 %; p = 0.0009),
which would be advantageous for the latter group, al-
though most other significant or non-significant differ-
ences between the two groups, including younger age
(65 vs. 74; p < 0.0001) and a higher ratio of CR (86.2 vs.
60.0 %; p = 0.0052), were advantageous for the PCI group
(Table 1). On cranial MRI immediately before PCI, the
absence of BM was confirmed in 28 patients of the PCI
group (96.5 %) and in 57 patients of the non-PCI group
(60.0 %), presenting a significant difference (p < 0.0001)
and an advantage for the PCI group. No cranial CT
scans were performed.
Survival curves after the diagnosis of SCLC in 124 en-
rolled patients are shown in Fig. 1a. MSTs were 25 and
34 months in the PCI and non-PCI groups, revealing no
significant difference between the groups (p = 0.256). To
correct for differences in the disease stage, we only ana-
lyzed patients with stage III disease (Fig. 1b) and revealed
similar survival curves and MSTs (25 vs. 26 months, re-
spectively, p = 0.680). Curves for the cumulative occur-
rence of BM are shown in Fig. 2a and b. Among the 124
enrolled patients, BM developed at 2 years from diag-
nosis in 45.5 and 30.8 % in the PCI and non-PCI
groups, respectively (p = 0.313). Similarly, among pa-
tients only with stage III disease, occurrence rates
during 2 years were 42.3 and 52.3 % in the PCI and
non-PCI groups, respectively, and did not significantly
differ between the two groups (p = 0.458). Furthermore,
Table 1 Patient characteristics
All (n = 124) PCI (n = 29) non-PCI (n = 95) P
Age, year (range) 72 (37–88) 65 (37–74) 74 (37–88) <0.0001
Male 113 (91) 27 (93) 86 (90) 0.778
Smoking status 0.721
Current 61 (49) 15 (52) 46 (48)
Former 60 (48) 14 (48) 46 (48)
Never 2 (2) 0 2 (2)
Unknown 1 (1) 0 1 (1)
Number of packets 46 (0–210) 60 (12–140) 45 (0–210) 0.226
Clinical stage 0.0009
Stage I/II 51 (41) 5 (17) 46 (49)
Stage III 73 (59) 24 (83) 49 (52)
ECOG PS 0.337
0 70 (56) 20 (69) 50 (53)
1 50 (40) 8 (28) 42 (44)
2 4 (3) 1 (3) 3 (3)
Initial treatment 0.094
Chemoradiotherapy 61 (49) 19 (66) 42 (44)
Radiotherapy 4 (3) 0 (0) 4 (4)
Surgery 41 (34) 8 (28) 33 (35)
Chemotherapy 18 (15) 2 (7) 16 (17)
Response to initial treatment 0.0052
Complete response 82 (66) 25 (86) 57 (60)
Good partial response 42 (34) 4 (14) 38 (40)
Cranial MRI before PCI 85 (69) 28 (97) 57 (60) <0.0001
Observation period (month) 20 (6–94) 20 (6–82) 20 (6–94) 0.945
Data are numbers of patients (percentage of patients) otherwise indicated
PCI prophylactic cranial irradiation; ECOG PS Eastern Cooperative Oncology Group performance status
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we analyzed patients confirmed to not have BM with
cranial MRI after initial treatment. The BM occurrence
rates during 2 years were 43.0 and 38.4 % in the PCI
and non-PCI groups, respectively (p = 0.865).
During the observation period, 36 patients (29.0 %)
developed BM: 11 in the PCI group (37.9 %) and 25 in the
non-PCI group (26.3 %). Among them, 25 were asymp-
tomatic and 17 had only one intracranial lesion at the
initial detection of BM. Subsequently, 7 and 18 patients in
the PCI (63.6 %) and non-PCI (72.0 %) groups received
SRI therapy. Of these 25 patients, 11, 8, and 6 received γ-
knife, X-knife, and stereotactic radiotherapy, respectively.
All seven patients in the PCI group received SRI only
once. In contrast, six, three, and one patients received
two, three, and five separate sessions, respectively, of
salvage SRI therapy in the non-PCI group. WBRT was ad-
ministered as salvage therapy in 13 patients (41.7 %), 11 of
which belonged to the non-PCI group. Two patients in
the PCI group received WBRT for short-term palliation.
No patient underwent craniotomy.
Discussion
In the present study, we retrospectively evaluated the ef-
ficacy of PCI in patients with LS-SCLC, some of whom
received BM management with SRI and cranial MRI.
There was no significant difference in BM occurrence or
survival between patients with and without PCI.
PCI in patients with good responses to initial treat-
ment is highly recommended based on previous clinical
trials. In contrast, the present study revealed that pa-
tients with PCI did not benefit from BM management.
Fig. 1 Prophylactic cranial irradiation (PCI) and overall survival of all
patients (a) and of patients with stage III disease (b), M: months
Fig. 2 Prophylactic cranial irradiation (PCI) and cumulative incidence
of brain metastases among all enrolled patients (a) and in those
with stage III disease (b), M: months
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There are some differences between previous studies
and the present study. At first, high incidence of BM
examination using cranial MRI was observed: 96.5 and
60.0 % in the PCI and non-PCI groups, respectively. On
the other hand, all but two trials did not require con-
firmation of the absence of BM before PCI [1–4, 6–20],
which raised the possibility that these previous trials
contained more patients actually having BM at the time
of PCI. Because BM screening confirmed that patients
were free from BM and that patients without BM may
represent a better prognostic population [22], the cranial
MRI after initial treatment would be one of the primary
causes. In the present study, the cumulative incidence of
BM in patients who did not receive PCI was only
30.8 %, which is lower than that previously reported
(50–60 %).
Although there is no available data about the efficacy
of PCI with the adaptation of SRI, reports indicating
the benefit of SRI in patients with SCLC have been in-
creasing. Harris et al. reported that patients with SCLC
who developed BM after PCI or WBRT and were
treated by γ-knife had an MST of 5.9 months despite
poor prognostic backgrounds [24]. Wegner et al. re-
ported that BM occurrences after PCI in patients with
SCLC were efficiently salvaged with SRI, and the MST
in those SRI-treated patients was 9 months [28]. Sur-
vival benefit, at least partly owing to SRI, can lower the
contribution of PCI on survival, which may explain the
results of the present study. Thus, although PCI re-
mains strongly recommended based on previously re-
ported benefits, these benefits may be attenuated if the
management with MRI and SRI is available
Neurologic toxicities of PCI were not assessed in the
present study. The association between neurological tox-
icity and PCI has been debatable since the past 30 years
[29–31]. The PCI strategy involving irradiation of brains
in patients with LS-SCLC for treating undetectably small
BM has reasonably provided a 50–60 % incidence of BM
after the initial treatment. However, recent prospective
studies, including two trials for PCI [32, 33] and two for
WBRT [33, 34], have shown substantial cognitive impair-
ments after whole brain irradiation. Gondi et al. demon-
strated an association between PCI and declines in
Hopkins Verbal Learning Test and self-reported
cognitive function between 410 patients with PCI and
173 control patients who did not develop BM [32].
Uno et al. reported that only 12 of the 139 patients with
LS-SCLC (8.6 %) received PCI in Japan [35], possibly
because of concerns about the neurocognitive impair-
ment. Although it is generally considered that the bene-
fits of PCI should be favorably weighed against the
associated adverse effects, we need to reconsider the
benefits of PCI based on the understanding of exact
adverse effects.
There are limitations to the present study. First, the
sample size was small, which may not particularly be
sufficient for analyzing the survival time because of con-
siderably lesser expectancy of risk reduction, 14–18 % in
survival time, while 50–68 % is reported in the BM pre-
vention [1–4, 36]. Second, the number of patients in this
retrospective study was unequal in the two groups. Fur-
thermore, the limited number in the PCI group could
affect the statistical power for detecting the benefits of
PCI. A higher ratio of early clinical stage in the non-PCI
group would be advantageous for the non-PCI group, and
younger age, higher ratios of CR and MRI confirmed ab-
sences of BM were advantageous for the PCI group, which
may limit the current results. However, it is not realistic to
interventionally and prospectively verify the benefit of PCI
at present, and we believe our study can offer the oppor-
tunity to reconsider the adaptation of PCI. Additional ana-
lysis with patients with stage III disease reproduced
similar survival and BM occurrence curves in those with
and without PCI. The absence of clear criteria for the
adaptation of PCI, cranial MRI, and SRI, which were indi-
vidually decided by the physicians, is another major limi-
tation. Considering these limitations, we must recognize
that the results of our retrospective study are not practice-
changing and further studies are needed to confirm our
results.
Conclusion
This retrospective study suggests that treatments with
PCI did not relate the benefit in BM occurrence or sur-
vival in patients for whom SRI and MRI were available.
Thus, in the situation that the adaptation of SRI and
MRI are available for the management of BM, PCI may
be less beneficial than previously reported. Based on the
current results, a further prospective, observational
study is in progress.
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